Vena, Antonio http://orcid.org/0000-0002-0697-3992
Bassetti, Matteo http://orcid.org/0000-0002-0145-9740
Mezzogori, Laura http://orcid.org/0000-0001-5873-0856
Marchesi, Francesco http://orcid.org/0000-0001-6353-2272
Hoenigl, Martin http://orcid.org/0000-0002-1653-2824
Giacobbe, Daniele Roberto http://orcid.org/0000-0003-2385-1759
Corcione, Silvia http://orcid.org/0000-0003-2949-4297
Bartoletti, Michele http://orcid.org/0000-0002-1099-3283
Stemler, Jannik http://orcid.org/0000-0001-9152-2469
Pagano, Livio http://orcid.org/0000-0001-8287-928X
Cornely, Oliver A. http://orcid.org/0000-0001-9599-3137
Salmanton-García, Jon http://orcid.org/0000-0002-6766-8297
Funding for this research was provided by:
Universitätsklinikum Köln
Article History
Received: 28 March 2023
Accepted: 7 August 2023
First Online: 1 September 2023
Declarations
:
: Antonio Vena (AV) has participated on advisory boards and/or received speaker fees from Angelini, Menarini, Merck Sharp and Dohme, Pfizer, and Shionogi. He has also received study grants from Merck Sharp and Dohme and Astellas, outside of the submitted work. Matteo Bassetti (MB) has participated on advisory boards and/or has received speaker fees from Achaogen, Angelini, Astellas, Bayer, Basilea, Biomerieux, Cidara, Gilead Sciences, Menarini, Merck Sharp and Dohme, Nabriva, Paratek, Pfizer Inc., Roche, Melinta Therapeutics, Shionogi, Tetraphase, VenatoRx, and Vifor. He has also received study grants from Angelini, Basilea, Astellas, Shionogi, Cidara, Melinta, Gilead Sciences, Pfizer, and Merck Sharp and Dohme, outside of the submitted work. Laura Mezzogori (LM) has no conflict of interest to disclose. Francesco Marchesi (FM) has no conflict of interest to disclose. Martin Hoenigl (MH) received research funding from Gilead, Astellas, MSD, IMMY, Scynexis, F2G and Pfizer, outside of the submitted work. Daniele Roberto Giacobbe (DRG) has received investigator-initiated grants from Pfizer Inc, Shionogi, Gilead Italia, as well as speaker fees and/or advisory board fees from Pfizer and Tillotts Pharma, outside of the submitted work. Silvia Corcione (SC) has no conflict of interest to disclose. Michele Bartoletti (MB) has no conflict of interest to disclose. Jannik Stemler (JS) has received research support by the Ministry of Education and Research (BMBF) and Basilea Pharmaceuticals Inc., outside the submitted work; has received speaker honoraria by Pfizer Inc., Gilead and AbbVie, outside the submitted work; has been a consultant to Gilead, Produkt&Markt GmbH, Alvea Vax. and Micron Research, outside the submitted work; and has received travel grants by German Society for Infectious Diseases (DGI e.V.) and Meta-Alexander Foundation, outside the submitted work. Livio Pagano (LP) was Board member of Gilead Science, MSD, Pfizer, Stemline, Basilea, Janssen-Cilab, Novartis, Jazz Pharmaceutical, Cidara and has been speaker for Gilead Sciences, Kiowa Kirin, MSD, Pfizer Pharmaceuticals, Astellas Pharma, Novartis, Jazz Pharmaceutical, Janseen-Cilag. Consultant for Menarini, Cidara, outside of the submitted work. Oliver A. Cornely (OAC) reports grants or contracts from Amplyx, Basilea, BMBF, Cidara, DZIF, EU-DG RTD (101037867), F2G, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; Consulting fees from Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Noxxon, Octapharma, PSI, Scynexis, Seres; Honoraria for lectures from Abbott, Al-Jazeera Pharmaceuticals, Astellas, Grupo Biotoscana/United Medical/Knight, Hikma, MedScape, MedUpdate, Merck/MSD, Mylan, Pfizer; Payment for expert testimony from Cidara; Participation on a Data Safety Monitoring Board or Advisory Board from Actelion, Allecra, Cidara, Entasis, IQVIA, Janssen, MedPace, Paratek, PSI, Shionogi; A patent at the German Patent and Trade Mark Office (DE 10 2021 113 007.7), outside of the submitted work. Jon Salmanton-García (JSG) reports speaker honoraria from Gilead and Pfizer, outside of the submitted work.
: Not applicable.